Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. reports recurring updates about its pharmaceutical royalty business, which owns rights to royalties from licensed pharmaceutical products and no longer conducts research and development or commercial operations. The company’s news is centered on license revenue, primarily under the Mayne License Agreement, changes in sales of licensed products, operating expense levels after its transition to a royalty-based model, and results from continuing operations.
TherapeuticsMD also provides corporate strategy updates, including disclosures about its ongoing evaluation of strategic alternatives. Its historical context includes a December 2022 shift from a women’s healthcare commercialization business to a company focused on collecting royalties from licensees.
TherapeuticsMD (NASDAQ:TXMD) has launched Just Say Vagina, a campaign aimed at empowering women to openly discuss reproductive health issues. Comedian Whitney Cummings, who has utilized the ANNOVERA® contraceptive, will be featured, encouraging women to abandon euphemisms in favor of direct communication about their needs. The press release highlights that 45% of unintended pregnancies in the U.S. stem from inconsistent contraceptive use, and 47% of women discontinue birth control due to dissatisfaction.
TherapeuticsMD, Inc. (NASDAQ:TXMD) has successfully closed an underwritten public offering of 23,437,500 shares of its common stock, generating net proceeds of approximately $27.5 million after deducting underwriting discounts and commissions. All shares were sold by TherapeuticsMD, with Cantor Fitzgerald & Co. serving as the sole bookrunning manager. The offering was conducted under a previously declared effective shelf registration statement with the SEC.
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 a.m. Eastern time. Investors can access a live webcast of the presentation on the company’s website. TherapeuticsMD focuses on developing innovative products for women's healthcare, addressing issues in family planning, reproductive health, and menopause management. The company aims to enhance women’s health and raise awareness of their healthcare challenges.
TherapeuticsMD (NASDAQ:TXMD) announced the pricing of its public offering of approximately 23.4 million shares, aiming for gross proceeds of $30 million. The offering is set to close around November 12, 2020, pending customary conditions. A 30-day option for underwriters to purchase an additional 3.5 million shares is also granted. The proceeds will fund the commercialization of three FDA-approved products: IMVEXXY, BIJUVA, and ANNOVERA, as well as working capital and general corporate purposes.
TherapeuticsMD, Inc. (NASDAQ:TXMD) has announced an underwritten public offering of its common stock, granting the underwriter a 30-day option to purchase an additional 15% of shares. The proceeds will primarily be used for the commercialization of its three FDA-approved products: IMVEXXY®, BIJUVA®, and ANNOVERA®. Funds will also support working capital and general corporate purposes. Cantor Fitzgerald & Co. is the sole bookrunning manager for this offering.
TherapeuticsMD, Inc. (NASDAQ:TXMD) reported a significant 80% increase in net revenue to $19.3 million for Q3 2020, surpassing estimates for the sixth consecutive quarter. This growth was driven by a 62% rise in product sales to $17.3 million. The company reduced operating expenses by $11.0 million, totaling $37.1 million. Notably, ANNOVERA revenue soared by 250% to $6.4 million, while IMVEXXY and BIJUVA also showed strong performance. The company is exploring the divestiture of vitaCare, potentially unlocking over $50 million in non-dilutive proceeds for shareholders.
TherapeuticsMD Inc. (NASDAQ: TXMD) has partnered with POPSUGAR to launch a new women's health platform called Full Disclosure, which promotes its contraceptive product, ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system). This innovative platform aims to foster open discussions about women’s health, covering topics like fertility and pregnancy, without stigma. The initiative responds to the growing demand for longer-acting contraceptives, emphasizing ANNOVERA's unique non-invasive application.
TherapeuticsMD, Inc. (NASDAQ:TXMD) emphasizes the necessity for women to consult healthcare providers regarding sexual and reproductive health options. The company promotes treatments such as ANNOVERA and IMVEXXY through awareness campaigns. Recently, ANNOVERA garnered increased demand across various distribution channels. In recognition of Menopause Awareness Month, TherapeuticsMD launched a series aimed at improving discussions surrounding menopause and its symptoms. The company continues to advocate for women's healthcare and communication with providers.